IWAA 2017 20th Annual Scientific Session

Coeur d'Alene, ID US
July 20, 2017 to July 22, 2017

Didactic lectures allowing speakers to provide evidence based medical recommendations, updates and expert opinions in an efficient manner.
 

Accreditation  
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Intermountain West Allergy Association (IWAA) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
This activity is supported in part by independent medical education grants from Boston Scientific, DBV Technologies and Stallergenes Greer.

 

Target Audience

Practicing allergists, fellows-in-training, primary care physicians and allied healthcare providers in the field of allergy and immunology.

 

 

Learning Objectives

        

-Identify common and uncommon clinical presentations of immunological or allergic disease

-Describe the benefits and limitations of medication classes presently available to treat immunological or allergic disease

-Assess the evidence base on new and emerging therapies for immunological or allergic disease.

-Discuss recent advances in the understanding of pathophysiology of immunological or allergic disease.

Additional information
Disclosure: 

IWAA 2017 20th Annual Scientific Session

July 20-22,2017

Coeur d’Alene, Idaho

 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

 

All identified conflicts of interest have been resolved.

 

Mariana Castells, M.D., Ph.D.                     Speaker

Advisory Board:  Merck

Consultant: Bentham Science, Lytix Biopharma, Sanofi

Other:  Contracted Research:  Genentech

 

Richard Henry, M.D.                                       Moderator

Other:  Primary Investigator: AstraZeneca, Genentech, Roche, Sanofi

 

Jim Patel, M.D.                                                 Speaker

Speaker:  Bayer, Boehringer Ingenheim, Boston Scientific

 

Raffi Tachdjian, M.D.                                     Speaker

Advisory Board:  CSL Behring, Pharming, Shire

Consultant:  CSL Behring

Speaker:  Alcon, CSL Behring, Horizon, Mylan, Shire, Teva

 

Carl Thornblade, M.D.                                   Moderator

Advisory Board:  Circassia

Independent Contractor:  Circassia, Teva

 

The following have no relevant financial relationships to disclose:

Amal Assa’ad, M.D.                                        Speaker

Linda Cox, M.D.                                                Speaker

Jeffrey Demain, M.D.                                     Speaker

Ronald England, MD.                                     Moderator

Jim Thompson PhD                                         Speaker

Gregory Wickern, M.D.                                 Moderator

Doug Huneywell                                              Meeting Administrator

 

Course summary
Available credit: 
  • 13.75 AMA PRA Category 1 Credit™
  • 13.75 Attendance
Course opens: 
07/20/2017
Course expires: 
07/22/2019
Event starts: 
07/20/2017 - 7:00pm CDT
Event ends: 
07/22/2017 - 5:00pm CDT
Add to calendar: 
Rating: 
0
Coeur d'Alene
115 S. 2nd Street
Coeur d'Alene, ID 83814
United States
+1 (855) 703-4648

Accreditation  

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Intermountain West Allergy Association (IWAA) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Available Credit

  • 13.75 AMA PRA Category 1 Credit™
  • 13.75 Attendance
Please login or create an account to take this course.